Drugs / AdCLD-CoV19
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04666012 | Dec 2020 → Jul 2021 | COVID-19 | Cellid Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AdCLD-CoV19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04666012 ↗ |
| Modality | Vaccine | “COVID-19 Preventive Vaccine” NCT04666012 ↗ |
| Route | Intramuscular | “Subject will receive single dose of AdCLD-CoV19 as intramuscular injection.” NCT04666012 ↗ |